Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TP63 |
| Gene Name: | TP63 |
| Protein Full Name: | Tumor protein 63 |
| Alias: | EEC3; KET; LMS; NBP; OFC8; p51; p53CP; p63; p73H; p73L; SHFM4; TA p63 alpha; TP53CP; TP53L; TP63; TP73L; tumor protein p63 |
| Mass (Da): | 76785 |
| Number AA: | 680 |
| UniProt ID: | Q9H3D4; C9D7C9; C9D7D0; C9JW72 |
| Locus ID: | 8626 |
| COSMIC ID: | TP63 |
| Gene location on chromosome: | 3q28 |
| Cancer protein type: | MIXED |
| Effect of cancer mutation on protein: | MIXED |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 20026 |
| Percent of cancer specimens with mutations: | 1.33 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | TP63 may act as a transcriptional activator or repressor, depending on its isoform. It may be required for the initiation of p53/TP53-dependent apoptosis. It is involved in Notch signalling by inducing JAG1 and JAG2 and regulates epithelial morphogenesis. Defects have been associated with cervical, colon, head and neck, lung, and ovarian cancers. However, tumour suppressor and oncogenic properties are isoform-dependent. Isoforms lacking the N-terminal transcriptional activation domain play oncogenic roles. |